文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

一项前瞻性II期研究:基于前列腺特异性抗原动力学的挽救性放疗联合68Ga-PSMA-PET治疗根治性前列腺切除术后生化复发——PROPER 1试验

A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-07-05

这项II期试验纳入100例根治性前列腺切除术后生化复发患者,基线行PSMA-PET,挽救性放疗至50 Gy时根据PSA反应(≥0.15 ng/mL为无反应)调整方案。97例可分析,反应者34例、无反应者63例;3年无失败生存率反应者94%、无反应者68%,PSMA-PET附加价值有限。

要点

  • 挽救性放疗50 Gy时PSA≥0.15 ng/mL的无反应者接受序贯淋巴结照射及PSMA-PET阳性病灶推量。
  • 反应者组PSMA-PET阳性3例(9%),无反应者组22例(35%),差异有统计学意义(p=0.007)。
  • 3年无失败生存率反应者94%、无反应者68%,中位随访38个月。

核心结论

  • 基于PSA反应的个体化挽救性放疗强化方案在反应者和无反应者中均显示出高肿瘤控制率。
  • 结果提示该方案在原本预后较差的患者组中具有临床显著效果且副作用中等。
  • PSMA-PET附加价值有限,该治疗策略目前正在一项III期试验中评估。

研究设计与样本

  • 前瞻性II期试验(PROPER 1),纳入100例根治性前列腺切除术后生化复发患者。
  • 基线行PSMA-PET,挽救性放疗期间每周检测PSA。
  • 初始处方为前列腺床70 Gy分35次,放疗在50 Gy后进行调整。
  • 无反应者(PSA仍≥0.15 ng/mL)接受序贯淋巴结照射及PSMA-PET阳性病灶推量,反应者(PSA<0.15 ng/mL)按计划继续挽救性放疗。
  • 仅在50 Gy后PSA无反应时才将PET结果纳入治疗计划考虑。

主要发现

  • 97例患者数据可分析,34例归类为反应者,63例为无反应者。
  • PSMA-PET阳性在反应者组为3例(9%),在无反应者组为22例(35%)(p=0.007)。
  • 3年无失败生存率反应者为94%,无反应者为68%(中位随访38个月)。
  • 医生报告泌尿和肠道毒性无显著差异。
  • 患者报告腹泻在挽救性放疗结束时无反应者中更常见。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The treatment of biochemical recurrence (BCR) after prostatectomy is challenging as the site of the recurrence is often undetectable. Our aim was to test a personalised treatment concept for BCR based on PSA kinetics during salvage radiotherapy (SRT) combined with prostate-specific membrane antigen positron emission tomography (PSMA-PET). MATERIALS AND METHODS: This phase II trial included 100 patients with BCR. PSMA-PET was performed at baseline. PSA was measured weekly during SRT. Initially, 70 Gy in 35 fractions was prescribed to the prostate bed. Radiotherapy was adapted after 50 Gy. Non-responders (PSA still ≥ 0.15 ng/mL) received sequential lymph node irradiation with a boost to PSMA-PET positive lesions, while responders (PSA < 0.15 ng/mL) continued SRT as planned. PET-findings were only taken into consideration for treatment planning in case of PSA non-response after 50 Gy. RESULTS: Data from 97 patients were eligible for analysis. Thirty-four patients were classified as responders and 63 as non-responders. PSMA-PET was positive in 3 patients (9%) in the responder group and in 22 (35%) in the non-responder group (p = 0.007). The three-year failure-free survival was 94% for responders and 68% for non-responders (median follow-up 38 months). There were no significant differences in physician-reported urinary and bowel toxicity. Patient-reported diarrhoea at end of SRT was more common among non-responders. CONCLUSION: This new personalised treatment concept with intensified SRT based on PSA response demonstrated a high tumour control rate in both responders and non-responders. These results suggest a clinically significant effect with moderate side effects in a patient group with otherwise poor prognosis. PSMA-PET added limited value. The treatment approach is now being evaluated in a phase III trial.Clinical trial registration numbers: NCT02699424&ISRCTN45905321.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gunnlaugsson A, Johannesson V, Wieslander E, et al. A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial. Clin Transl Radiat Oncol. 2022. PMID: 35873652. doi:10.1016/j.ctro.2022.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。